Galectin Therapeutics to Present at 2015 Ladenburg Thalmann Healthcare Conference

NORCROSS, Ga., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that Peter G. Traber, M.D., chief executive officer, president, and chief medical officer of Galectin Therapeutics, will make a corporate presentation at the 2015 Ladenburg Thalmann Healthcare Conference on September 29th at 11 a.m. Eastern Time. The conference is being held at the Sofitel Hotel in New York City.

To listen to the presentation, investors may visit the investor relations section of Galectin Therapeutics' website at www.galectintherapeutics.com. An archived audio of the presentation will also be available on Galectin Therapeutics' website for 90 days.

About Galectin Therapeutics

Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.

CONTACT: Jack Callicutt, Chief Financial Officer
         (678) 620-3186
         [email protected].

         LHA
         Kim Golodetz
         (212) 838-3777
         [email protected]

You May Also Be Interested In

• PZZA INVESTIGATION: Papa John's Investors Should Contact Block & Leviton To Possibly Recover Losses
• Tracy Young, MSNA, MBA, CRNA, Named 2026-27 President of the American Association of Nurse Anesthesiology
• Nearly One-Third of CRE Asset Managers Make Major Capital Decisions on Gut Instinct, New Survey Finds